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Methods 961 patients referred for PS were referred for PS and electro-
physiological study (EPS). Clinical history, echocardiography and treat-
ment were collected. Patients were followed from 3 months up to 10 years
(5.3±5 years).
Results There were 72 patients ≥60y (mean 68.5±6), 889 patients <60y
(mean 30.5±14). Electrophysiological data and recourse to accessory
pathway (AP) ablation (43% vs. 48.5%, p=0.375) did not significantly differ
between the two groups. Older patients more often had symptomatic forms
(81% vs. 63%, p=0.003) and more often had history of spontaneous atrial
fibrillation (AF)(8% vs. 3%, p=0.01) or poorly-tolerated arrhythmias
(18%vs. 7%, p=0.0009). In multivariable analysis, patients ≥60 had a sig-
nificantly higher risk of history of AF (OR=4.2, 2.1-8.3, p=0.001) and
poorly-tolerated arrhythmias (OR=3.8, 1.8-8.1, p=0.001). In patients who
underwent AP ablation, age ≥60 was associated with an increased risk of
major complication (9.6% vs. 1.9%, p=0.006). During follow-up, occurrence
of AF (13.9% vs. 3.6%, p<0.001) and poorly-tolerated tachycardia (4.2% vs.
0.6%, p=0.001) were more frequent in patients ≥60 although frequency of
ablation failure or recurrence was similar (20% vs. 15.5%, p=0.52). In mul-
tivariable analysis, patients ≥60 had a significantly higher risk of AF
(OR=2.9, 1.2-6.8, p≤0.01).
Conclusions Referring of older patients was infrequent in our clinical prac-
tice (7.5% of patients with a PS). Patients ≥60 have a higher risk of AF and
poorly-tolerated tachycardia both at admission and during follow-up but also
a higher risk of procedure complications. Nevertheless, given a risk of
important complications below 10%, the risk/benefit balance appears to favor
AP ablation in the elderly.
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Introduction Treatment of chronic hepatitis C virus (HCV) infection has
dramatically improved since the advent of direct anti-viral agents, including
Sofosbuvir. Sustained virological response may be achieved in more than 90%
of patients without interferon, ensuring broad use of these regimens. To date,
several thousands of patients have been treated with Sofosbuvir-based regi-
mens worldwide. Since their approval in France, combination therapy is given
to patients with complications, including cirrhosis and life-threatening extra-
hepatic manifestations. 
Methods We analyzed retrospectively the incidence of arrhythmias and
conduction disorder in a cohort of patients treated by Sofosbuvir (new anti-
viral HCV) in our hospital from January 2, 2014 to December 31, 2014. 
Results We observed five cases (1.2%) of severe arrhythmia, including
three cardiac conduction defects, within the first days of Sofosbuvir-based
therapy among 415 patients who had been treated in our center. There
were two females and three males. The median age was 58 (50-75) years.
Two patients were coinfected with HIV. Arrhythmia relapsed when Sofos-
buvir was reintroduced in one patient. Among the 3 conduction disorders,
one patient was under beta-blocker and amiodarone another. A pacemaker
was implanted in all 3 patients with conduction disorders. The three
patients who underwent a pacemaker implantation were not pacemaker-
dependent, on the controls after stopping antiviral treatments (figure 1). 
Conclusion Sofosbuvir seems to have cardiac toxicity. The mechanism
underlying Sofosbuvir cardiotoxicity has to be determined. A particular
attention should be given to patients with a medical history of rhythm
or  conduction abnormalities, including careful monitoring (e.g., Holter
ECG recordings) of cardiac rhythm during the first days of Sofosbuvir
therapy.
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Background Preexcitation syndrome (PS) is a potential cause of sudden
cardiac death; its prognostic assessment is a major issue. The aim was to
assess the contribution of esophageal electrophysiological study (EPS) com-
pared to intracardiac EPS for the prognostic evaluation in patients with PS.
Methods We conducted a prospective single-centre study between
November 1st, 2008 and December 1st, 2014, in patients who underwent both
esophageal and intracardiac EPS for a PS. Accessory pathway effective refrac-
tory period (APERP) and induction of sustained supraventricular tachyarrhyth-
mias (SVT) were noted for both methods.
Results 69 patients were included. 45 (65%) were males and mean age was
36±16 years. There were no significant differences in the induction of SVT
between both methods. APERPs were significantly shorter at esophageal EPS
compared to intracardiac EPS in control state (>40 ms) in 51% of patients, but
APERPs did not decrease significantly after isoproterenol: in these patients
with shorter APERP at esophageal EPS, age and gender was similar to other
patients; APERPs in basal state were shorter than in patients with similar
APERPs at both studies (255±43 vs 281±61)(p0.032), but APERPs after iso-
proterenol were similar (226±33 vs 231±45)(0.55); the shortening of APERP
after infusion of isoproterenol was significantly less than in patients with sim-
ilar APERPs at esophageal and intracardiac EPS (30±31ms vs 49±45
ms)(p<0.05). The sensitivity of esophageal EPS in prognostic assessment was
88% in control state, 100% during isoproterenol infusion. The area under
ROC curve of transesophageal EPS in prognostic assessment based on APERP
measurement was 0.74.
Conclusion Esophageal EPS was a reliable and sensitive method of prog-
nostic assessment in patients with PS. APERP was shorter in 51% of patients
but did not decrease significantly after isoproterenol at esophageal EPS
compared to intracardiac EPS, indicating esophageal EPS-related stress.
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Background Heart rate variability and autonomic nervous system dysfunc-
tion have a recognised value in the assessment of the prognostic of heart dis-
ease and it is well known that variability decreases with age and in heart
failure or ischemic patients, as a predictor for worsen outcome and for an
increase in mortality and morbidity.
Materials and methods We retrospectively investigated 12 lead Holter
ECG monitoring in the past 2 years for ischemic patients aged 50 or older who
had ventricular arrhythmias. We included in our observational study
25 patients, 16 women and 9 men with a mean age of 64,71±9,09. For each of
the participants we evaluated the heart rate variability parameters: SDNN,
SDANN, MSSD, pNN50.
Results Our analysis revealed that there is a good correlation between the
number of ventricular escape beats on a 24 hours monitoring and the heart rate
variability parameters SDNN (y=8,7266x – 757,02 R2=0,8171) and rMSSD
(y=8,6658x – 65,347 R2=0,6395).
Conclusions The results may be a starting point for future research for
improving the prognostic in elderly with cardio-vascular disease, taking into
consideration that both parameters (heart rate variability and ventricular
arrhythmias) may be influenced and improved either by adequate physical
activity or by antiarrhythmic drugs with strong implications in deciding for
primary and secondary prevention.
The author hereby declares no conflict of interest
0324
Prognostic value of epicardial-endocardial gradient measured by
echocardiography to predict Cardiac Resynchronization Therapy
(CRT) response
Frederic Sebag*, Laura Ernande, Nicolas Mignot, Nicolas Lellouche
APHP-CHU Henri Mondor, Créteil, France
*Corresponding author: dr.fsebag@gmail.com (Frederic Sebag)
Background As right ventricular lead is positioned endocardialy and left
ventricular lead epicardialy, we hypothesized that baseline epi-endo gradient
could predict CRT response.
Method and results We studied 46 patients referred for CRT. Transtho-
racic echocardiography (TTE) was performed for all patients before and one
year after implantation. Offline analysis with speckle tracking imaging (STI)
analysis of LV endocardial and epicardial wall was performed. Specifically,
epi-endo gradient delay (GD) and gradient contraction (GC) measurements
were performed on the septal and lateral LV wall before and one year after
implantation. CRT response was defined as a reduction>15% of LV end sys-
tolic volume one year after CRT.
Results Mean age was 62±11 year-old and mean EF was 26±7%. Twenty-
two patients were classified as responders. Baseline characteristics of patients
with or without CRT response were similar, except for QRS duration. Before
implantation, septal (10±31ms vs. 20±133 ms, p=0.67) and lateral GD
(1±25ms vs. 4±26 ms, p=0.76) were low and similar in both groups. However
lateral GC was higher in CRT responders (–4.05±2.29% vs. –2.38±2.82%,
p=0.009). After multivariate analysis, lateral GC was the best predictor of
CRT response (p=0.013). One year after implantation, septal GD and GC were
comparable in CRT responders or not. However lateral GC significantly
decreased in CRT responders (–4.05±2.29% at baseline vs. –1.86±2.2%,
p<0.01) whereas no changes were observed for non-responders. Finally lateral
GD was significantly increased at one year in CRT non responders 4±26ms at
baseline vs. 18±43 ms, p<0.01).Conclusion: At baseline no significant LV
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